Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 in heterozygous familial hypercholesterolemia
NL-OMON39059Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in familial hypercholesterolemia (FH) (4 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in LDL cholesterol at week 12. Started Apr 2013; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON39059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39059.